GLOW Peptide Dosage in the Research Literature — GHK-Cu, BPC-157, TB-500
GLOW Peptide Dosage in the Research Literature
GLOW peptide dosage data comes from separate studies on each of the three constituent peptides — GHK-Cu, BPC-157, and TB-500 — not from any published study of the combined blend. The dose ranges and routes described below are drawn from preclinical rodent and canine models and, in GHK-Cu's case, from human clinical studies. This is a summary of what researchers have administered in controlled settings, not a recommendation for any dose or route in humans. The GLOW blend has not been evaluated in a controlled clinical trial.
Dosing ranges observed in GLOW peptide studies
In preclinical research, BPC-157 has been administered at doses ranging from 10 pg/kg to 10 μg/kg intraperitoneally in rodent wound, tendon, and myotendinous junction models, with full functional recovery observed at all three dose levels in some models [10][11]. Oral administration via drinking water at 0.16 μg/mL (approximately 2 mL per rat per day) produced equivalent effects to intraperitoneal injection in several wound-healing studies [11]. In cell culture, BPC-157 increased growth hormone receptor expression at concentrations of 0.25–0.5 μg/mL in tendon fibroblast studies [12].
GHK-Cu has been studied in vitro at 1–10 nanomolar concentrations for collagen and elastin effects, at 7.5 mg/kg twice daily (intraperitoneal) in the mouse cognitive protection study [5], and at 15 mg/kg/day intranasally in the aged mouse spatial memory study [6]. Topical clinical studies used unspecified concentrations in formulated creams; the 6-month randomized hair trial used topical ALAVAX at 50 mg/mL and 100 mg/mL concentrations [4].
TB-500 wound reepithelialization effects were observed with topical and intraperitoneal administration in rats; the in vitro keratinocyte migration assay documented activity at 10 picograms [17]. Formal dose-ranging studies for TB-500 in rodent wound models were not consistently reported in the retrieved literature.
Pharmacokinetic half-life of GLOW blend constituents
BPC-157 has the most thoroughly characterized pharmacokinetics of the three. In rats and beagle dogs, elimination half-life after IV and IM administration is below 30 minutes, with peak plasma concentration reached within 3–9 minutes of administration [13]. Intramuscular bioavailability is 14–19% in rats and 45–51% in dogs, with linear kinetics across doses studied. BPC-157 is metabolized into small peptide fragments then single amino acids via normal proteolytic pathways, excreted through urine and bile.
GHK-Cu plasma half-life formal data was not identified in the retrieved literature. Endogenous plasma GHK levels are approximately 200 ng/mL at age 20, declining to below 60 ng/mL by age 60; copper binding may prolong local tissue residence relative to free peptide. Formal half-life data for TB-500 was not identified in the retrieved literature; its Ac-SDKP metabolite is generated in vivo from Tβ4 by meprin and prolyl oligopeptidase, suggesting that the anti-fibrotic activity of TB-500 may outlast the parent compound. No half-life or pharmacokinetic data exists for the GLOW triple combination as a formulated blend [13].
How long does GLOW peptide take to work?
Animal studies on the constituent peptides suggest observable tissue changes within days to weeks. In BPC-157 wound models, prominent fibroblast proliferation with collagen fiber synthesis was visible at day 7 in myotendinous junction injury models; full functional recovery with corrected collagen alignment occurred by day 28 [10]. In TB-500 wound studies, reepithelialization increased by 42% at day 4 and 61% at day 7 [17]. GHK-Cu's documented effects in clinical studies emerged over 12-week and 6-month trial periods [1][4]. Human timelines for the GLOW blend have not been established in controlled trials. These animal-model and clinical observations are from studies of each constituent peptide individually, not of the combined formulation.
Cycling protocols observed in GLOW peptide research
No controlled trial has validated a specific cycle duration for the GLOW blend. Clinic protocols for research peptide blends typically describe 30-day active cycles followed by 14–21 day rest periods, reflecting convention from constituent-peptide preclinical cycling studies rather than any directly tested protocol. Some protocols describe 5 days on with 2 days off as an alternative pattern. BPC-157's elimination half-life below 30 minutes in rodents [13] suggests that persistent tissue-level effects are driven by repeated administration rather than cumulative systemic accumulation. Neither cycle length nor cycle frequency has been validated in a human clinical trial for any of the three constituents as injected compounds.
Injection Protocols in GLOW Peptide Research
Subcutaneous injection is the predominant route described in preclinical and observational clinic literature for peptide blend administration. Intraperitoneal administration was the standard route in most BPC-157 and TB-500 rodent studies; in translated clinical-context protocols, subcutaneous injection is the closest practical analog to intraperitoneal. In BPC-157 wound studies, topical, oral, and intraperitoneal routes produced equivalent effect sizes across all dose levels studied [11], indicating that the compound is not route-specific in its wound-healing effects. GHK-Cu was studied topically in clinical settings and intranasally and intraperitoneally in rodent models; subcutaneous injection would bypass the limited topical skin permeation (~3.86% penetration for unmodified GHK) documented in the 2024 review [7].
Injection site considerations in pre-clinical GLOW protocols
Subcutaneous injection is the predominant route described in preclinical and observational clinic literature; proximal-to-site-of-interest administration is sometimes noted in protocols where the target tissue is accessible. In animal models, intraperitoneal injection delivered systemic distribution. For research protocols, the primary documented routes across the three constituents are subcutaneous (SC), intraperitoneal (IP in animals), oral, and topical. No human pharmacokinetic comparison of SC versus other routes for the combined GLOW formulation has been published.
Reconstitution of GLOW peptide blend
Lyophilized peptide blends require reconstitution with bacteriostatic water before use. Reference protocols describe adding 2.5–3 mL of bacteriostatic water (0.9% benzyl alcohol) to the lyophilized vial, using gentle circular swirling rather than vigorous shaking to avoid peptide denaturation, and storing the reconstituted solution refrigerated. BPC-157 is stable in human gastric juice for more than 24 hours [11]; lyophilized peptides generally maintain stability at −20°C for 24 months and at 4°C for up to 90 days after reconstitution when stored correctly. The benzyl alcohol preservative in bacteriostatic water inhibits microbial growth and extends the shelf life of reconstituted solutions compared to sterile water without preservative.
Bacteriostatic water volume for GLOW reconstitution
Reference protocols describe 2.5–3 mL of bacteriostatic water per standard 70 mg GLOW vial, yielding a concentration that delivers common dose units at approximately 12 insulin-syringe units (0.12 mL). These are observed protocol conventions from clinic settings, not values validated in a published controlled trial. The appropriate reconstitution volume depends on vial fill mass, and the resulting concentration should be calculated from the known fill mass of each constituent peptide, not from a general protocol reference.
Dosing frequency in GLOW peptide research protocols
Observational clinic data describes daily subcutaneous injection for 30-day cycles with a rest period; some protocols use 5 days on with 2 days off. BPC-157's sub-30-minute plasma half-life [13] suggests that local tissue concentration, not systemic accumulation, drives the repair effects — which is consistent with once- or twice-daily dosing frequencies in preclinical studies. GHK-Cu was administered twice daily in the mouse cognitive study [5] and once daily in the intranasal aging study [6]. No human dosing-frequency optimization trial has been published for any of the three constituents as injectable compounds.